Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Sana Biotechnology Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.32, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| EWU | SANA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.68 | $5.92 |
52-Week Low | $40.90 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.37, down 0.25% on the day, with a bullish technical outlook supported by moving averages and strong trend indicators like ADX. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake. The ETF is influenced by FTSE 100 performance, oil price volatility, and UK political developments under new Prime Minister Andy Burnham.
The outlook for EWU is cautiously optimistic, driven by bullish technical signals and exposure to UK equities, but risks from Middle East tensions, oil price swings, and political uncertainty may curb gains. Investors should weigh the ETF's diversification benefits against macroeconomic headwinds affecting British markets.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
